ANI Pharmaceuticals, Inc. is scheduled to announce its third-quarter earnings for 2025 before the market opens on November 7, 2025. Analysts anticipate that the company will report earnings of $1.74 per share, with expected revenues reaching approximately $211.917 million for the quarter. The announcement will be followed by a conference call at 8:30 AM ET, offering stakeholders an opportunity to hear the latest updates directly from the company.
In its previous earnings report, released on June 8, 2025, ANI Pharmaceuticals reported a loss of ($0.12) earnings per share, generating revenues of $64.48 million. The company recorded a negative net margin of 1.37%, yet achieved a positive return on equity of 25.03%. For the current fiscal year, analysts predict ANI Pharmaceuticals will achieve an earnings per share figure of $4, with similar expectations for the following year.
Market Performance and Recent Insider Activity
On Thursday, shares of ANI Pharmaceuticals opened at $92.62, reflecting a decline of 2.0%. The stock has fluctuated significantly over the past year, with a low of $52.50 and a high of $99.50. Currently, the company boasts a market capitalization of $2.01 billion and a debt-to-equity ratio of 1.39. Analysts have noted a P/E ratio of -120.28 and a beta of 0.54, indicating its relative stability amidst market fluctuations.
In a recent development regarding insider trading, Chad Gassert, Senior Vice President, sold 20,000 shares of the company on August 15 for a total of $1,739,400. This transaction represented a 10.35% reduction in his holdings, leaving him with 173,226 shares valued at approximately $15.07 million. Additionally, Stephen P. Carey, Chief Financial Officer, sold 50,000 shares on August 12, netting around $4,303,500 and reducing his stake by 21.66%.
In total, insiders have sold 413,830 shares of ANI Pharmaceuticals in the last quarter, amounting to $36.5 million. Corporate insiders now hold 12.70% of the company’s stock.
Institutional Investment Trends
Recent activity from institutional investors indicates a cautious but steady interest in ANI Pharmaceuticals. Canada Life Assurance Co increased its stake by 1.0% in the second quarter, now holding 19,408 shares valued at approximately $1.27 million. Similarly, Thrivent Financial for Lutherans boosted its holdings by 2.6%, acquiring an additional 321 shares during the same period.
UBS Asset Management also increased its stake by 0.9%, purchasing 423 shares and bringing its total ownership to 48,322 shares valued at about $3.24 million. Other notable changes include Advisors Asset Management Inc., which acquired a new position valued at approximately $28,000, and MIRAE ASSET GLOBAL ETFs HOLDINGS Ltd., which raised its holdings by 4.5%.
Currently, institutional investors and hedge funds collectively own 76.05% of ANI Pharmaceuticals, signaling strong institutional confidence in the company’s long-term potential.
As ANI Pharmaceuticals prepares for its upcoming earnings announcement, stakeholders will be closely monitoring the figures to assess the company’s financial health and market outlook.
